Skip to content
OpenCapital
Get started

Edgewell Personal Care EPC Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

Perrigo Company logo
Perrigo CompanyPRGO
——
Coty logo
CotyCOTY
——

Other financials

Income statement

See full
Revenue$519.5M+0.6%
Gross profit$216.9M-8.4%
Operating income$18.4M-62.4%
Net income-$10.6M-137%
EPS (diluted)-$0.22-137%

Balance sheet

See full
Cash & equivalents$299.7M+76.2%
Total debt$1.3B-13.4%
Total equity$1.4B-4.3%
Total assets$3.5B-6.4%

Cash flow

See full
Operating cash flow-$125.9M-8.9%
CapEx$14.0M-18.1%
Free cash flow-$137.5M-3.9%

Valuation

See full
Market cap$1.22B+12.1%
Enterprise value$2.2B-8.1%
P/S0.6×+0.1×

Profitability

See full
Gross margin40.6%-2.8pp
Operating margin6.4%-3.8pp
Net margin3.1%-2.2pp
FCF margin-15.6%—

Returns & leverage

See full
Return on equity4.1%-3.5pp
Debt / equity0.9×-0.1×
Current ratio1.8×-0.1×

Where this comes from

Reported directly by Edgewell Personal Care in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Edgewell Personal Care’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewell Personal Care's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewell Personal Care's indefinite-lived research and development assets?
Edgewell Personal Care (EPC) reported indefinite-lived research and development assets of $569.5M in Q1 2026.
How has Edgewell Personal Care's indefinite-lived research and development assets changed year-over-year?
Edgewell Personal Care's indefinite-lived research and development assets decreased by 4.3% year-over-year, from $595.3M to $569.5M.
What is the long-term trend for Edgewell Personal Care's indefinite-lived research and development assets?
Over 5 years (2020 to 2025), Edgewell Personal Care's indefinite-lived research and development assets has grown at a -1.0% compound annual growth rate (CAGR), from $601.4M to $571.4M.